PRNP and early-onset autosomal dominant Alzheimer disease: Moreover, anti-PrP antibodies that block the interaction between PrPC and Aβ aggregates attenuate toxicity and cognitive deficits in rodents and thus are being considered for use as an Alzheimer’s disease therapeutic [95–98].